Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 12, 2012, Pages 2006-2010

  Mori, Shunsuke ^a   Ueki, Yukitaka ^b   Hirakata, Naoyuki ^b   Oribe, Motohiro ^c   Hidaka, Toshihiko ^d   Oishi, Kazunori ^e  

^a Kumamoto Saishunsou National Hospital   (Japan)

^b SASEBO CHUO HOSPITAL   (Japan)

^c Oribe Rheumachika Naika Clinic   (Japan)

^d Zenjinkai Shimin No Mori Hospital   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INFLUENZA VACCINE; METHOTREXATE; TOCILIZUMAB; TRIPLE VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNITY; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROCONVERSION; SEROLOGY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INFLUENZA, HUMAN; METHOTREXATE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 84868510039     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201950     Document Type: Article

References (20)

1. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
2. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191-4.
3. Kapetanovic MC, Saxne T, Nilsson JA, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007;46:608-11.
4. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272-9.
5. Kubota T, Nii T, Nanki T, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007;17:531-3.
6. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67:713-16.
7. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010;39:442-7.
8. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNF alpha blockers: safety and immunogenicity. Clin Immunol 2010;134:113-20.
9. Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 2010;4:263-78.
10. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988;167:332-44.
11. Shinoki T, Hara R, Kaneko U, et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. Published Online First: 11 February 2012.
12. Committee for proprietary medical products (CPMP). Note for guidance on harmonization of requirements for influenza vaccination. London: The European Agency for the Evaluation of Medicinal Products (EMEA/CPMP/BMP/214/96). 1997:1-18.
13. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-42.
14. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
15. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
16. Costelloe KE, Smith SH, Callard RE. Interleukin 6 is not required for antigen-specific antibody responses by human B cells. Eur J Immunol 1993;23:984-7.
17. Uchiyama Y, Yorozu K, Hashizume M, et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull 2008;31:1159-63.
18. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002;29:2555-7.
19. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011;63:1486-96.
20. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47:249-55.